Hubei Jumpcan Pharmaceutical Past Earnings Performance
Past criteria checks 6/6
Hubei Jumpcan Pharmaceutical has been growing earnings at an average annual rate of 13.6%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 9% per year. Hubei Jumpcan Pharmaceutical's return on equity is 21.1%, and it has net margins of 30.9%.
Key information
13.6%
Earnings growth rate
10.6%
EPS growth rate
Pharmaceuticals Industry Growth | 10.9% |
Revenue growth rate | 9.0% |
Return on equity | 21.1% |
Net Margin | 30.9% |
Next Earnings Update | 24 Aug 2024 |
Recent past performance updates
Recent updates
Is Hubei Jumpcan Pharmaceutical (SHSE:600566) A Risky Investment?
Aug 07Is Now The Time To Put Hubei Jumpcan Pharmaceutical (SHSE:600566) On Your Watchlist?
Jul 01Hubei Jumpcan Pharmaceutical Co., Ltd.'s (SHSE:600566) Prospects Need A Boost To Lift Shares
May 30Hubei Jumpcan Pharmaceutical (SHSE:600566) Ticks All The Boxes When It Comes To Earnings Growth
Mar 17Revenue & Expenses Breakdown
How Hubei Jumpcan Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 9,669 | 2,991 | 4,268 | 472 |
31 Dec 23 | 9,655 | 2,823 | 4,376 | 464 |
30 Sep 23 | 9,639 | 2,523 | 4,565 | 635 |
30 Jun 23 | 9,762 | 2,495 | 4,687 | 595 |
31 Mar 23 | 9,211 | 2,266 | 4,536 | 566 |
31 Dec 22 | 8,996 | 2,171 | 4,513 | 553 |
30 Sep 22 | 8,115 | 2,039 | 4,087 | 556 |
30 Jun 22 | 7,811 | 1,881 | 4,049 | 551 |
31 Mar 22 | 7,888 | 1,861 | 4,126 | 539 |
31 Dec 21 | 7,631 | 1,719 | 4,039 | 523 |
30 Sep 21 | 7,260 | 1,590 | 3,926 | 281 |
30 Jun 21 | 6,896 | 1,446 | 3,761 | 267 |
31 Mar 21 | 6,074 | 1,252 | 3,277 | 267 |
31 Dec 20 | 6,165 | 1,277 | 3,306 | 244 |
30 Sep 20 | 5,868 | 1,277 | 3,068 | 238 |
30 Jun 20 | 5,984 | 1,344 | 3,113 | 229 |
31 Mar 20 | 6,868 | 1,577 | 3,636 | 212 |
31 Dec 19 | 6,940 | 1,623 | 3,707 | 210 |
30 Sep 19 | 7,050 | 1,685 | 3,806 | 208 |
30 Jun 19 | 7,311 | 1,809 | 3,943 | 200 |
31 Mar 19 | 7,160 | 1,731 | 3,890 | 197 |
31 Dec 18 | 7,208 | 1,688 | 3,917 | 196 |
30 Sep 18 | 6,972 | 1,625 | 3,785 | 181 |
30 Jun 18 | 6,636 | 1,484 | 3,537 | 266 |
31 Mar 18 | 6,365 | 1,400 | 3,474 | 218 |
31 Dec 17 | 5,642 | 1,223 | 3,176 | 166 |
30 Sep 17 | 5,385 | 1,165 | 3,064 | 129 |
30 Jun 17 | 5,134 | 1,076 | 3,095 | 0 |
31 Mar 17 | 4,926 | 1,016 | 2,987 | 0 |
31 Dec 16 | 4,678 | 934 | 2,854 | 0 |
30 Sep 16 | 4,458 | 864 | 2,749 | 0 |
30 Jun 16 | 4,249 | 796 | 2,639 | 0 |
31 Mar 16 | 4,020 | 736 | 2,508 | 0 |
31 Dec 15 | 3,768 | 687 | 2,362 | 0 |
30 Sep 15 | 3,585 | 640 | 2,260 | 0 |
30 Jun 15 | 3,392 | 595 | 2,167 | 0 |
31 Mar 15 | 3,178 | 553 | 2,032 | 0 |
31 Dec 14 | 2,986 | 519 | 1,899 | 0 |
30 Sep 14 | 2,829 | 490 | 1,810 | 0 |
30 Jun 14 | 2,664 | 461 | 1,693 | 0 |
31 Mar 14 | 2,524 | 429 | 1,627 | 0 |
31 Dec 13 | 2,448 | 403 | 1,601 | 0 |
Quality Earnings: 600566 has high quality earnings.
Growing Profit Margin: 600566's current net profit margins (30.9%) are higher than last year (24.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 600566's earnings have grown by 13.6% per year over the past 5 years.
Accelerating Growth: 600566's earnings growth over the past year (32%) exceeds its 5-year average (13.6% per year).
Earnings vs Industry: 600566 earnings growth over the past year (32%) exceeded the Pharmaceuticals industry -0.5%.
Return on Equity
High ROE: 600566's Return on Equity (21.1%) is considered high.